• Product name
    Anti-SUZ12 antibody [EPR5234(N)] (HRP)
    See all SUZ12 primary antibodies
  • Description
    Rabbit monoclonal [EPR5234(N)] to SUZ12 (HRP)
  • Host species
  • Conjugation
  • Tested applications
    Suitable for: WBmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Mouse, Rat
  • Immunogen

    Synthetic peptide within Human SUZ12 aa 50-150 (Cysteine residue). The exact sequence is proprietary.
    Database link: Q15022

  • Positive control
    • WB: SW480, HeLa, MCF-7 and HEK293 whole cell lysates.
  • General notes

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.



Our Abpromise guarantee covers the use of ab196976 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/3000. Detects a band of approximately 83 kDa (predicted molecular weight: 83 kDa).


  • Function
    Polycomb group (PcG) protein. Component of the PRC2/EED-EZH2 complex, which methylates 'Lys-9' (H3K9me) and 'Lys-27' (H3K27me) of histone H3, leading to transcriptional repression of the affected target gene. The PRC2/EED-EZH2 complex may also serve as a recruiting platform for DNA methyltransferases, thereby linking two epigenetic repression systems. Genes repressed by the PRC2/EED-EZH2 complex include HOXC8, HOXA9, MYT1 and CDKN2A.
  • Tissue specificity
    Overexpressed in breast and colon cancer.
  • Involvement in disease
    Note=A chromosomal aberration involving SUZ12 may be a cause of endometrial stromal tumors. Translocation t(7;17)(p15;q21) with JAZF1. The translocation generates the JAZF1-SUZ12 oncogene consisting of the N-terminus part of JAZF1 and the C-terminus part of SUZ12. It is frequently found in all cases of endometrial stromal tumors, except in endometrial stromal sarcomas, where it is rarer.
  • Sequence similarities
    Belongs to the VEFS (VRN2-EMF2-FIS2-SU(Z)12) family.
    Contains 1 C2H2-type zinc finger.
  • Developmental stage
    Expressed at low levels in quiescent cells. Expression rises at the G1/S phase transition.
  • Cellular localization
  • Information by UniProt
  • Database links
  • Alternative names
    • ChET 9 protein antibody
    • CHET9 antibody
    • Chromatin precipitated E2F target 9 protein antibody
    • JJAZ1 antibody
    • Joined to JAZF1 protein antibody
    • KIAA0160 antibody
    • Polycomb protein SUZ12 antibody
    • Suppressor of zeste 12 homolog antibody
    • Suppressor of zeste 12 protein homolog antibody
    • SUZ12 antibody
    • SUZ12 polycomb repressive complex 2 subunit antibody
    • SUZ12_HUMAN antibody
    see all


  • All lanes : Anti-SUZ12 antibody [EPR5234(N)] (HRP) (ab196976) at 1/3000 dilution

    Lane 1 : Wild-type HAP1 whole cell lysate
    Lane 2 : SUZ12 knockout HAP1 whole cell lysate

    Lysates/proteins at 20 µg per lane.

    Predicted band size: 83 kDa
    Observed band size: 83 kDa

    Exposure time: 20 minutes

    ab196976 was shown to specifically react with SUZ12 in wild-type HAP1 cells as signal was lost in SUZ12 knockout cells. Wild-type and SUZ12 knockout samples were subjected to SDS-PAGE. Ab196976 and ab184095 (Mouse monoclonal [mAbcam 9484] to GAPDH - Loading Control (Alexa Fluor® 680) loading control) were incubated overnight at 4°C at 1/3000 dilution and 1/20000 dilution respectively. The loading control was imaged using the Licor Odyssey CLx prior to blots being developed with ECL technique.

  • All lanes : Anti-SUZ12 antibody [EPR5234(N)] (HRP) (ab196976) at 1/3000 dilution

    Lane 1 : SW480 (Human colon adenocarcinoma cell line) Whole Cell Lysate
    Lane 2 : HeLa whole cell lysate (ab150035)
    Lane 3 : MCF7 (Human breast adenocarcinoma cell line) Whole Cell Lysate
    Lane 4 : HEK293 (Human embryonic kidney cell line) Whole Cell Lysate

    Lysates/proteins at 10 µg per lane.

    Developed using the ECL technique.

    Performed under reducing conditions.

    Predicted band size: 83 kDa
    Observed band size: 83 kDa

    Exposure time: 20 minutes

    This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 3% milk before being incubated with ab196976 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.


ab196976 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab196976.
Please use the links above to contact us or submit feedback about this product.


Sign up